Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Based on metabolism and clearance a clinically significant interaction with emtricitabine is unlikely as dacarbazine undergoes activation to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. However, in vitro data suggest that dacarbazine is a substrate of the renal transporter OAT1 and concentrations of tenofovir and dacarbazine could be increased due to competition for active tubular secretion. No a priori dosage adjustment is recommended but renal function and haematological parameters should be monitored.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking